key: cord-0777660-eztqbv1k
authors: Siawasch, S. A. M.; Andrade, C.; Castro, A. B.; Teughels, W.; Temmerman, A.; Quirynen, M.
title: Impact of local and systemic antimicrobials on leukocyte- and platelet rich fibrin: an in vitro study
date: 2022-02-17
journal: Sci Rep
DOI: 10.1038/s41598-022-06473-4
sha: 84cc7940650638875f26fb774ae3787f41285859
doc_id: 777660
cord_uid: eztqbv1k

The aim of this study was to evaluate the effect of local and systemic administration of antimicrobials to leukocyte- and platelet-rich fibrin (L-PRF). For part A, 16 tubes of venous blood were collected from each of eight systemically healthy subjects. Prior to blood centrifugation, 12 of the 16 tubes were injected with 0.125 ml, 0.25 ml or 0.50 ml metronidazole solution. One set of L-PRF membranes was used to assess the release of vascular endothelial growth factor AB, platelet-derived growth factor, transforming growth factor beta 1, and bone morphogenetic protein 2 at indicated time points. The metronidazole release over time by L-PRF membranes was also evaluated. The remaining L-PRF membranes were placed on the surface of agar plates inoculated with three different periodontal pathogens to determine their antibacterial activity. For part B, another six subjects were enrolled with three subjects taking 2 g amoxicillin and three subjects 500 mg metronidazole as prophylaxis prior to a periodontal treatment. Before and 2 h after consuming one of the prescribed antimicrobials, three tubes of blood were collected for preparing L-PRF membranes. These membranes were used to measure the antibacterial activity against periodontal pathogens. No statistically significant difference could be found in the release of growth factors between L-PRF membranes with and without incorporation of metronidazole solution. The release of metronidazole could be detected up to day 3, however with the highest concentration during the first 4 h. This concentration was dose dependent. The antibacterial capacity of L-PRF membranes increased significantly for both the systemic intake, and after the addition of metronidazole solution to the blood tubes before centrifugation, the latter again dose dependent. The antibacterial capacity of L-PRF against the periodontal pathogens tested can significantly be enhanced by the addition of antimicrobials, without disadvantage for the release of growth factors.

www.nature.com/scientificreports/ depending on the preparation protocol [9] [10] [11] 13 . For preparing L-PRF, red tubes filled with fresh blood are centrifuged at a relative centrifugal force in area where L-PRF clot is formed (RCF clot ) of 408 g for 12 min. The centrifugation protocol for A-PRF and A-PRF + is a RCF clot of 193 g for 14 min and a RCF clot of 245 g for 8 min, respectively 14 . Unfortunately, the available literature does not provide clear evidence in significant clinical advantage of one above the other. The regenerative potential of PRF allows to use it as sole filling biomaterial in different periodontal and implant therapy. Beneficial effects have been described during sinus floor elevation, alveolar ridge preservation, periodontal plastic surgery, and regeneration of intra-bony defects [15] [16] [17] [18] [19] . Moreover, the application of PRF in conjunction with another bio-active material has also been described in the literature. A mixture of PRF with a xenograft bone substitute can be used for guided bone regeneration procedure 20, 21 . Furthermore, PRF has been combined with drugs like metformin, statin, and bisphosphonate to promote the healing capacity of PRF 22-27 . In another study, L-PRF has been modified with silver nanoparticles to improve the mechanical properties and antibacterial activity 28 .

A recent publication proposed to use L-PRF as a delivery system for antimicrobials 29 . In this article, different volumes of metronidazole, clindamycin or penicillin solutions were directly added to the blood tubes prior to centrifugation. This resulted in a significantly higher antibacterial activity against F. nucleatum and Staphylococcus aureus compared to L-PRF without antimicrobials. However, the addition of more than 0.5 ml of antimicrobial solutions negatively affected the physical properties of L-PRF membranes.

Another research group reported the same innovative approach with PRP for treating orthopaedic infections 30 . PRP clots were prepared with and without the addition of antimicrobials such as vancomycin, clindamycin, and ceftazidime. Similar to pure antimicrobials, PRP clots with antimicrobial solutions showed a significant inhibition of S. aureus, Escherichia coli and Pseudomonas aeruginosa. Despite that most of the antimicrobials were released after the first 10 min, a significant higher minimum inhibitory concentration (MIC) could be detected after 3 days. The release of growth factors maintained the same levels only when a low dose (1 mg) of antimicrobials was added to PRP.

As mentioned above, L-PRF and its modifications could have a beneficial effect in terms of antibacterial activity after the addition of antimicrobials. However, it is crucial to understand which concentrations of antimicrobials can provide this significant advantage. Furthermore, it is also essential to ascertain the effect of those concentrations on the biological properties of L-PRF. And last, potential adverse effects of antimicrobials to living cells in L-PRF should be taking in consideration. As determined in previous studies, L-PRF membrane contain about 50-70% of leukocytes from the initial blood sample 20, 31 . Therefore, awareness should be paid to leukocyte chemotaxis and leukopenia induced by antimicrobials 32, 33 .

The aim of this study was to evaluate the effect of administration of local and systemic antimicrobials on the release of growth factors and antibacterial activity by L-PRF membranes. It is hypothesized that low concentrations of antimicrobials will not affect the release of growth factors, but it will increase the antibacterial capacity of L-PRF membranes.

Population and study design. Systemically healthy volunteers were invited to participate in this study.

The exclusion criteria for study enrolment were as follows: under the age of 18 years, American Society of Anesthesiology (ASA) score III or IV, use of antimicrobials in the past 6 months, use of alcohol till 3 days before the venepuncture, smoking, and pregnancy/lactation. Prior to the participation, all included subjects received information about the study purposes, and gave both verbally and written informed consent. All methods were carried out with the approval of the Ethical Committee Research UZ/KU Leuven (study number S58789, third amendment). The Helsinki Declaration as well the regulations of University Hospitals Leuven were respected. Further government guidelines regarding to COVID-19 were strictly followed.

The study was divided in two parts. Part A was set up to determine the effect of direct administration of local antimicrobials to the blood prior to centrifugation and part B to assess the effect of systemic antimicrobials (Fig. 1) .

For part A, sixteen tubes of blood were collected from each of the eight participants to prepare L-PRF membranes. Four tubes were directly placed to the centrifuge, while in the remaining tubes 0.125, 0.25 or 0.50 ml metronidazole solution (500 mg/100 ml) [Flagyl®, Sanofi Belgium, Diegem, BE] was injected before centrifugation. The metronidazole solution was injected in the tubes with a sterile 1-ml syringe with 26-gauge needle [BD Plastipak™, Becton Dickinson, Franklin Lakes, New Jersey, USA]. So, at the end four membranes without antimicrobial (control) and twelve membranes injected with three different concentrations of metronidazole were obtained. From those sixteen membranes, four membranes (one control and one with respectively 0.125, 0.25 and 0.50 ml of metronidazole) were used to measure the release of growth factors and the release of metronidazole. The remaining twelve membranes (three controls and three with respectively 0.125, 0.25 and 0.50 ml of metronidazole) were used for determination of the antibacterial activity against periodontal pathogens P. gingivalis, P. intermedia, and F. nucleatum.

For part B, six patients in the need of periodontal treatment were enrolled. Each patient donated three tubes of blood before the intake of antimicrobial, and another three tubes 2 h thereafter. Three of the six patients consumed 2 g amoxicillin [Amoxicilline Sandoz®, Sandoz NV, Vilvoorde, BE] per os as endocarditis prophylaxis. Further, 500 mg metronidazole [Flagyl®, Sanofi Belgium, Diegem, BE] per os was administered as a periodontal adjunct to the other three participants. For this part of the study, only the antibacterial capacity of the L-PRF membranes was determined against the same three periodontal pathogens as in part A. All tubes were as soon as possible (< 1 min) centrifuged [Intraspin™, Intra-Lock, Boca Raton, Florida, USA] at RCF clot 408 g for 12 min at 2700 rpm. After centrifugation the red blood cells were gently removed and the L-PRF clot was placed in a compression box [Xpression® box, Intra-Lock, Boca Raton, Florida, USA]. After 5 min of gentle compression, the exudate was squeezed out of the clot and L-PRF membranes were formed. All L-PRF membranes were weighted immediately after preparation.

After measuring the weight, four L-PRF membranes were separately placed into a polypropylene tube of 15 ml and filled with 5 ml of Dulbecco's Modified Eagle medium [Gibco™, Thermo Fisher Scientific, Waltham, Massachusetts, USA]. One of the L-PRF membranes was without antimicrobial and the other three with 0.125 ml, 0.25 ml, and 0.50 ml of metronidazole, respectively. The tubes were incubated at 37 °C for 4 h. Then, the L-PRF membranes were transferred to new polypropylene tubes, filled with 5 ml of the new medium, and incubated till day 1. This procedure was repeated on day 3, 7, and 14. After removing the L-PRF membranes from the tubes, the remaining medium was centrifuged [VWR™ Mega Star 6000R, VWR International BVBA, Leuven, BE] for 10 min at 1000 rpm to remove the residue. After that, the medium in each tube was distributed over 5 Eppendorf tubes of 1 ml and stored at − 80 °C. After collecting all samples from all volunteers, the release of growth factors and metronidazole was measured for all membranes at each selected time points.

Enzyme-linked immunosorbent assay (ELISA) was used to quantify the release of specific growth factors such as platelet-derived growth factor-AB (PDGF-AB), vascular endothelial growth factor (VEGF), transforming growth factor beta 1 (TGF-β 1 ) [R&D Systems Europe, Abingdon, UK] and bone morphogenetic protein 2 

To quantify the release of metronidazole, high-performance liquid chromatography (HPLC) [Agilent 1200 Series Gradient HPLC, Agilent Technologies, Santa Clara, California, USA] was performed. A volume sample of 10 µL was injected into the reversed phase column (Phenomenex Luna® C18(2), 5 µm, 100A, 250 × 4.6 mm) [Phenomenex B.V., Utrecht, NL] with the temperature maintained at 30 °C. The mobile phase was 70% 0.1 M monopotassium phosphate (KH 2 PO 4 ) and 30% Acetonitrile (CH 3 CN) with a flow rate of 1 ml/min. The retention time and total runtime were 3.6 and 10 min, respectively. The ultraviolet detection wavelength was set at 318 nm and the standard calibration curve was y = 26,56 × with R 2 = 0,9997.

Antibacterial capacity of L-PRF membranes. The antimicrobial activity of L-PRF membranes was analysed against P. gingivalis (ATCC 33277), P. intermedia (ATCC 25611), and F. nucleatum (ATCC 20482) by using agar diffusion test. Those periodontal pathogens are gram-negative and anaerobic, so they could be cultured under the same conditions. An overnight culture was prepared for all bacterial strains. All three bacterial species were cultured in brain heart infusion (BHI) [Difco™, Thermo Fisher Scientific, Waltham, Massachusetts, USA] growth medium and incubated under anaerobic conditions (37 °C, 80% N 2 , 10% H 2 and 10% CO 2 ). Bacterial concentration was determined with an optical density (OD) of 500 nm by diluting the overnight culture with BHI. Two hours before the venepuncture, blood agar plates [Oxoid, Basingstoke, UK] were inoculated with 100 µl of that suspension by using a sterile cotton swab [Aptaca S.p.A., Canelli, Asti, IT]. The blood agar plates were directly incubated in anaerobic conditions. Once the L-PRF membranes were prepared, they were placed on the inoculated plates and incubated in anaerobic conditions for 3 days. Prior and 72 h after the incubation, a standardised picture of the agar plates was taken. Measurements of the inhibition distances were performed with ImageJ® version 1.53i [Image Processing and Analysis in Java, 1.8.0_172] software. Four different lines were drawn from the border of the L-PRF membrane to the border of the inhibition zone and finally the average inhibition was calculated. A fixed ruler next to the agar plates was used as a help tool to calibrate the measurements (Fig. 2) .

Procedures part B. The L-PRF membranes were prepared following the same protocol as for part A, but no metronidazole solution was added to any tubes. Also, the protocol for assessing the antibacterial activity with agar diffusion test was identical to part A. Unlike part A, the release of growth factors and antimicrobials was not determined.

A weighted linear mixed model was used to assess the comparisons between the groups. Patient was the random factor and the applied weights were inversely proportional to each group's variance. To check the normality of the residuals, normal quantile plots of the residual values were used. If required, log-or square root transformation of the data were performed before analysis. When the normal quantile plots showed that the presence of below-quantification limit data disturbed the assumption of normality of data, data were considered as presence or absence of growth factor or pathogen and analysed with a generalized linear mixed model for binary data using a logit link with patient as random factor. Sidak correction was used for all comparisons between groups for simultaneous hypothesis testing. P-values less than 0.05 were considered significant and post hoc analysis was conducted. All data were analysed using S-Plus 8.0 [Solution-Metrics, Sydney, Australia] for Linux.

Demographic data. Eight systemically healthy volunteers were included in part A of this study. The mean age was 37 years (SD ± 15 years). No complication was observed during blood collection.

Release of growth factors. The release of growth factors PDGF-AB, VEGF, TGF-β 1 and BMP-2 at indicated time points and as total accumulated quantities are summarized in Fig. 3A ,B, respectively. In general, a similar release pattern could be observed for PDGF-AB, VEGF, and TGF-β 1 with the most release in the first 3 time points. The release of BMP-2 was more irregular. No statistically significant differences (p > 0.05) could be detected among the four conditions: control L-PRF membranes and membranes with respectively 0.125, 0.25 and 0.50 ml metronidazole.

Release of metronidazole. The release of metronidazole was detected after 4 h and at day 1 and 3 (Fig. 4 ).

The first time point showed a high release with dose dependent statistical differences (p < 0.001).

Antibacterial capacity. The blood agar plate test revealed an inhibitory effect for all L-PRF membranes against the three periodontal pathogens ( www.nature.com/scientificreports/ lowest against P. intermedia. All three volumes of metronidazole contributed to a statistically significant higher inhibition distance compared to the control membranes (p < 0.01). The inhibition caused by L-PRF membranes modified with metronidazole solution was dose dependent.

Demographic data. Six systemically healthy volunteers were enrolled for this part of the study. The mean age was 49 years (SD ± 17 years). No complication was observed during blood collection.

Antibacterial capacity. An inhibitory effect against the three periodontal pathogens could be observed for both, L-PRF membranes prepared before and after consumption of oral antimicrobials by the participants ( Table 2 ). The membranes before antimicrobials consumption showed the highest inhibition distance against P. gingivalis and the lowest against P. intermedia. Consumption of amoxicillin resulted in significantly higher inhibition distance against all three pathogens (p < 0.01). After consumption of metronidazole a significant higher inhibition distance was found against P. gingivalis and F. nucleatum, but not against P. intermedia.

The aim of the present study was to determine if local and/or systemic administration of antimicrobials had an impact on the growth factors release and/or antibacterial activity of L-PRF membranes. For this purpose, the most commonly used antimicrobials in periodontics, such as amoxicillin and metronidazole were investigated 34 . The release of PDGF-AB, VEGF, TGF-β 1 , and BMP-2 were quantified at indicated time points and as total accumulated quantities. For all growth factors, a continuous release at each time point up to 14 days could be observed for both control L-PRF membranes and membranes modified with metronidazole solution. L-PRF membranes incorporated with metronidazole solution showed a similar pattern of release as control L-PRF membranes and no statistically significant differences could be detected in the amount of growth factors among the four groups. www.nature.com/scientificreports/ Two studies, discussed earlier in the introduction, have already examined the addition of antimicrobials to platelet concentrates. Ten milligrams ceftazidime or 100 mg vancomycin led to a significant reduction in release of growth factors PDGF-BB and TGF-β 1 by PRP. In addition, the administration of more than 0.5 ml antimicrobial solutions resulted in negative changes in physical properties of L-PRF 29, 30 . For this reason, in the current study no volumes of metronidazole solution higher than 0.5 ml were used. This was equal to 2.5 mg (500 mg/100 ml × 0.5 ml). Administration of local or systemic antimicrobials had no impact on L-PRF clot and membrane formation.

The quantification of the release of growth factors was performed with ELISA-kits. Because no ELISA-kit is available to analyse the antimicrobials in human serum, the release of metronidazole was verified via HPLC. This is a fast, effective, and reliable technique for determination of antimicrobials 35, 36 . According to previous studies, the release of antimicrobials by platelet concentrates can be detected up to 3 days if local antimicrobials are incorporated during the preparation procedure 29, 30 . In the present study, the release of metronidazole by modified L-PRF membranes could also be detected up to 3 days. As expected, no release from control membranes was found. For membranes incorporated with a metronidazole solution, the release was significantly higher at the first 4 h. Nevertheless, the detected concentrations at day 1 and 3 were still far above the MIC for periodontal pathogens 37, 38 .

Three different micro-organisms that have been implicated as predominant species during periodontal disease, were selected for assessing the antibacterial capacity of L-PRF membranes 39 . L-PRF membranes prepared without additional metronidazole solution (part A of the study) and prior to consumption of amoxicillin or metronidazole (part B of the study) exhibited small inhibition distances. The sequence of the highest inhibition Table 1 . Impact of metronidazole solution quantity on average bacterial inhibition distances by L-PRF membranes. Different letters indicate significant differences (p < 0.05) between the inhibition distances among the four conditions. SD standard deviation. Table 2 . Impact of amoxicillin and metronidazole prophylaxis on average bacterial inhibition distances by L-PRF membranes. AMOX amoxicillin, MET metronidazole, before prior to consumption of antimicrobial, after subsequent to consumption of antimicrobial, SD standard deviation. www.nature.com/scientificreports/ distances was against P. gingivalis followed by F. nucleatum and finally by P. intermedia. This natural antibacterial activity of L-PRF membranes cohered to a previous study 12 . Modification of L-PRF membranes with 0.125, 0.25 and 0.50 ml metronidazole solution resulted in significant higher and dose dependent antibacterial activity against all three pathogens. Likewise, greater antibacterial capacity was found after systemic administration of amoxicillin and metronidazole, except for metronidazole against P. intermedia. Local administration of the smallest volume (0.125 ml) of metronidazole solution directly to the blood tube caused already a higher inhibition distances against all three pathogens than 2 g amoxicillin or 500 mg metronidazole as one time prophylaxis. L-PRF membranes prepared after amoxicillin prophylaxis showed a higher inhibitory effect against P. gingivalis and P. intermedia than F. nucleatum. That could be explained by the fact that the susceptibility of P. gingivalis and P. intermedia to amoxicillin is higher compared to F. nucleatum. Likewise, the absence of an inhibitory effect after systemic administration of metronidazole could be the result of a low susceptibility of P. intermedia to metronidazole 40 . Susceptibility of anaerobic pathogens to antimicrobials depends on the relevant species, but also on the strain and region 41 .

For part B of the study, participants donated 2 times blood, once prior and 2 h after taking antimicrobial amoxicillin or metronidazole. The second time point coincides with the mean time that takes for those drugs to reach the maximum plasma concentration (T max ) 42 . From a technical point of view, the modification of antibacterial capacity of L-PRF seems to be easier by administrating systemic prophylaxis. However, this is less interesting when taking antimicrobial resistance into account 43 . Moreover, administration of antimicrobial solution to L-PRF tubes is not difficult, nor time-consuming, and also very simple.

This study demonstrated that addition of local antimicrobials to the L-PRF preparation procedure resulted in L-PRF membranes with significantly higher antibacterial capacity due to the release of the incorporated antimicrobial. Thus, L-PRF membranes may act as a local delivery system for antimicrobials to achieve a high concentration at infected sites, such as periodontal intra-bony defects. All drug delivery systems require a carrier that in the case of L-PRF would be the fibrin matrix. Fibrin-based matrices are well-known in tissue engineering because they contain numerous binding sites for cells, proteins, and growth factors 20 . However, previous studies reported rapid release in relative short time after antimicrobials were bound to fibrin sealants. This could be due to rapid diffusion and/or low binding affinity for specific antimicrobials [44] [45] [46] .

Incorporating L-PRF membranes with antimicrobials may bring concerns regarding global antimicrobial resistance (AMR). In part A of this study, metronidazole solution was injected directly into the blood tubes after venepuncture. In part B, six patients consumed systemic antimicrobials for medical purpose and the prescribed doses were according to the medical guidelines. So, none of the 14 subjects were unnecessary exposed to antimicrobials due to participation. With local administration of antimicrobials, a higher concentration can be reached in the intended site and less adverse effects are reported comparing to systemic use 47 . Nevertheless, local antibiotic may also contribute to AMR as has been shown in dermatology and ophthalmology 48, 49 . Incorporation of L-PRF membranes with antimicrobials should not be implement as a standard protocol. It is only reasonable to add antimicrobials to L-PRF if the antibacterial activity plays a major role to achieve treatment success. This modification is a contra-indication for cases where L-PRF is only used for his regenerative and angiogenic capacity. Therefore, the clinician should always make a good consideration.

Two limitations have to be taken into consideration while processing this in vitro study. First, the small sample size with eight participants in part A and six participants in part B. The post hoc analysis revealed that in some cases a significant difference in the release of growth factors may be found with a higher sample size (Supplementary Table S1 and S2). Second, no HPLC was performed to record the release of antimicrobials in time after systemic administration. Regardless these limitations, it is worth pointing out some strengths of this study. The present study proved that antibacterial activity of L-PRF membranes can significantly be enhanced by local administration of antimicrobials to the blood tubes or by systemic prophylaxis. In addition, this study proved that greater antibacterial activity can be archived with low concentrations of antimicrobials without affecting the release of growth factors by L-PRF membranes. At last, this study explored the opportunity of L-PRF membrane as a slow-release device.

Within the limitation of this study, we can conclude that administration of local and systemic antimicrobials provided L-PRF membranes with a significant greater antibacterial capacity against P. gingivalis, P. intermedia, and F. nucleatum. This benefit could be achieved with low concentrations of antimicrobials, which is important to maintain the biological and mechanical features of L-PRF. Now there is a need for randomized clinical trials to assess the clinical benefit of modified L-PRF membranes during periodontal and implant surgery. Possible research domains could be periodontal regenerative surgery, ridge preservation after extraction of infected tooth, and prevention of osteoradionecrosis of the jaw (ORJ) or medication-related osteonecrosis of the jaw (MRONJ). www.nature.com/scientificreports/

Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF)

Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part II: Platelet-related biologic features. Oral Surg

Platelet-rich fibrin (PRF): A second-generation platelet concentrate Part III: Leucocyte activation: A new feature for platelet concentrates

Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part IV: Clinical effects on tissue healing. Oral Surg

The influence of platelet-derived products on angiogenesis and tissue repair: A concise update

Comparison between PRP, PRGF and PRF: Lights and shadows in three similar but different protocols

Regenerative potential of leucocyte-and platelet-rich fibrin. Part A: intra-bony defects, furcation defects and periodontal plastic surgery A systematic review and meta-analysis

Regenerative potential of leucocyte-and platelet-rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy A systematic review

The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte-and platelet-rich fibrin (L-PRF) clot and membrane

Impact of g force and timing on the characteristics of platelet-rich fibrin matrices

Reduction of relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin (PRF)-based matrices: A proof of concept of LSCC (low speed centrifugation concept)

Antimicrobial capacity of leucocyte-and platelet rich fibrin against periodontal pathogens

Advanced platelet-rich fibrin: A new concept for cell-based tissue engineering by means of inflammatory cells

Standardization of relative centrifugal forces in studies related to plateletrich fibrin

Simultaneous sinus floor elevation and implant placement using leukocyte-and platelet-rich fibrin as a sole graft material

Effect of platelet-rich fibrin on alveolar ridge preservation: A systematic review

Use of platelet-rich fibrin for the treatment of periodontal intrabony defects: a systematic review and metaanalysis

Use of platelet-rich fibrin in the treatment of periodontal intrabony defects: a systematic review and meta-analysis

Use of platelet-rich fibrin for the treatment of gingival recessions: A systematic review and meta-analysis

Characterization of the leukocyte-and platelet-rich fibrin block: Release of growth factors, cellular content, and structure

Leucocyte-and platelet-rich fibrin block for bone augmentation procedure: A proof-of-concept study

Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial

A clinicoradiographic assessment of 1% metformin gel with platelet-rich fibrin in the treatment of mandibular grade II furcation defects

Platelet-rich fibrin combined with 1.2% atorvastatin for treatment of intrabony defects in chronic periodontitis: A randomized controlled clinical trial

Platelet-rich fibrin with 1% rosuvastatin for treatment of intrabony defects in chronic periodontitis: A randomized controlled clinical trial

Rosuvastatin 1.2 mg in situ gel combined with 1:1 mixture of autologous platelet-rich fibrin and porous hydroxyapatite bone graft in surgical treatment of mandibular class ii furcation defects: A randomized clinical control trial

Synergistic application of platelet-rich fibrin and 1% alendronate in periodontal bone regeneration: A meta-analysis

Does adding silver nanoparticles to leukocyte-and platelet-rich fibrin improve its properties?

Incorporating antibiotics into platelet-rich fibrin: A novel antibiotics slow-release biological device

Platelet-rich plasma loaded with antibiotics as an affiliated treatment for infected bone defect by combining wound healing property and antibacterial activity

Mechanical and structural properties of leukocyte-and platelet-rich fibrin membranes: An in vitro study on the impact of anticoagulant therapy

Effect of antibiotics of chemotaxis of human leukocytes

Hematologic impact of antibiotic administration on patients taking clozapine

Adjunctive effect of locally delivered antimicrobials in periodontitis therapy: a systematic review and metaanalysis

A simple and rapid liquid chromatographic method for the determination of metronidazole and its hydroxymetabolite in plasma and cutaneous microdialysates

New analytical method for the determination of metronidazole in human plasma: Application to bioequivalence study

Antibiotic susceptibility of putative periodontal pathogens in advanced periodontitis patients

Antimicrobial resistance of aggregatibacter actinomycetemcomitans, porphyromonas gingivalis and tannerella forsythia in periodontitis patients

Microbiology of periodontal diseases: A review

Susceptibility of Prevotella intermedia/Prevotella nigrescens (and Porphyromonas gingivalis) to propolis (bee glue) and other antimicrobial agents

Antimicrobial resistance and susceptibility testing of anaerobic bacteria

Farmacotherapeutisch Kompas

Antimicrobial advances in treating periodontal diseases

In vitro properties of mixtures of fibrin seal and antibiotics

Fibrin-antibiotic mixtures: an in vitro study assessing the possibility of using a biologic carrier for local drug delivery

Antibacterial effects of fibrin glue-antibiotic mixtures

Update on the adverse effects of antimicrobial therapies in community practice

Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts

Topical ocular antibiotics induce bacterial resistance at extraocular sites

Great appreciation goes to Dr. Martine Pauwels (Department of Oral Health Sciences, KU Leuven & Dentistry, University Hospitals Leuven, Leuven, Belgium) for her assistance in the laboratory and Dr. Wim Coucke (Scientific Institute of Public Health, Brussels, Belgium) for his support with the statistical analysis.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-06473-4.Correspondence and requests for materials should be addressed to S.A.M.S.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.